Figure 4From: Cardiovascular safety of linagliptin in type 2 diabetes: a comprehensive patient-level pooled analysis of prospectively adjudicated cardiovascular eventsHR estimates for secondary composite CV end points with linagliptin versus total comparators based on Cox hazard model. CI, confidence interval; CV, cardiovascular; FDA, Food and Drug Administration; HR, hazard ratio; MACE, major adverse CV events; MI, myocardial infarction.Back to article page